Evidence mapPaperPMID 22461539Full record

ArticleClinical journal of the American Society of Nephrology : CJASN2012

Cholesterol synthesis, cholesterol absorption, and mortality in hemodialysis patients.

Kyrill S Rogacev, Tobias Pinsdorf, Oliver Weingärtner, Markus K Gerhart, Elena Welzel, Kai van Bentum, Julius Popp, Andreas Menzner, Danilo Fliser, Dieter Lütjohann and 1 more

Registry-linked trialAbstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Clinical journal of the American Society of Nephrology : CJASN, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03480568 (A Phase III Trial to Evaluate the Efficacy and Safety of Biweekly Alirocumab in Patients on a Stable Dialysis Regimen), which is not on this map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
4.1field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03480568 phase3recruitingstarted 2018, after this paper: background citation

A Phase III Trial to Evaluate the Efficacy and Safety of Biweekly Alirocumab in Patients on a Stable Dialysis Regimen: The Alidial Study

Ran2018Enrolled20Registered outcomes5Posted comparisons0ConditionsAtherosclerotic Disease, Hemodialysis, Hypercholesterolemia, Peritoneal DialysisArmsAlirocumab 150 MG/ML [Praluent]
Open the trial in the graph
3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Observational
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Kyrill S RogacevDepartment of Internal Medicine IV, Nephrology and Hypertension, Saarland University Medical Center, Homburg, Germany.
Tobias Pinsdorf
Oliver Weingärtner
Markus K Gerhart
Elena Welzel
Kai van Bentum
Julius Popp
Andreas Menzner
Danilo Fliser
Dieter Lütjohann
Gunnar H Heine
Hypertension Institute · USSaarland University · DEInstitute of Clinical Research · USUniversity Hospital Bonn · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectivesRecent clinical trials on cholesterol-lowering in patients with CKD yielded conflicting results, which might have resulted from different treatment strategies. Serum cholesterol levels are determined by endogenous synthesis and intestinal absorption, which are differentially influenced by various classes of cholesterol-lowering agents. Assessing markers of cholesterol metabolism has thus been proposed for guidance of lipid-lowering therapy. This study analyzed surrogate markers of cholesterol absorption and synthesis in hemodialysis (HD) patients. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: In 113 HD patients, lathosterol was measured as a marker of cholesterol synthesis and cholestanol was measured as a marker of cholesterol absorption via gas chromatography. Controls were 229 healthy persons. Overall survival in HD patients was recorded over 3.4-year follow-up.

resultsCompared with controls, HD patients had lower lathosterol and higher cholestanol levels (P<0.001 for both). During follow-up, 58 patients died; higher cholestanol (indicating higher cholesterol absorption) predicted poor outcome among HD patients in multivariate Cox regression analysis after adjustment for potential confounders (hazard ratio for cholestanol above median, 2.24 [95% confidence interval (CI), 1.29-3.89]; P=0.004), whereas lower lathosterol (indicating lower cholesterol synthesis) did not (hazard ratio for lathosterol below median, 1.43 [95% CI, 0.81-2.50]; P=0.22).

conclusionsThis analysis of markers of cholesterol metabolism characterizes HD patients as cholesterol absorbers. In longitudinal analysis, higher levels of cholestanol were associated with all-cause mortality.

Indexed as

Intestinal AbsorptionAgedAged, 80 and overBiomarkersCase-Control StudiesCholestanolCholesterolChromatography, GasChronic DiseaseFemaleFollow-Up StudiesGermanyHumansKaplan-Meier EstimateKidney DiseasesMaleBiomarkersCholestanolCholesterollathosterol

Identifiers

PMID22461539
OpenAlexW2123121206

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.